CBP issued the following releases on commercial trade and related matters:
CBP issued the following releases on commercial trade and related matters:
CBP issued the following releases on commercial trade and related matters:
International Trade Today is providing readers with the top stories from Sept. 21-25 in case they were missed. All articles can be found by searching on the titles or by clicking on the hyperlinked reference number.
FDA is issuing new regulations that allow importation of prescription drugs from Canada. Under the final rule, FDA may approve “Section 804 Importation Programs” (SIPs) sponsored by a state, tribal or territorial governmental entity. The registered wholesaler or pharmacy identified by the SIP as the importer could then import the specified drug from an FDA-registered, Health Canada-licensed wholesaler that buys the drug directly from its manufacturer. The final rule is set for publication in the Oct. 1 Federal Register, and takes effect Nov. 30.
CBP issued the following releases on commercial trade and related matters:
The Animal and Plant Health Inspection Service released a notice Sept. 25 formally delaying its deadline for ACE filing of its “core” partner government agency (PGA) message set until January. “Due to the COVID-19 pandemic, APHIS has decided to delay implementation until January 25, 2021. On that date, APHIS intends to begin applying [Harmonized Tariff Schedule (HTS)] flags, which will alert filers, who opt to submit data electronically, whether APHIS import data is or may be required. Importers or brokers using ACE must enter APHIS-required import data when they receive an APHIS-specific HTS flag in order to complete their entry in the system,” the notice said. APHIS had announced the delay by email in June (see 2006300062).
CBP issued the following releases on commercial trade and related matters:
CBP issued the following releases on commercial trade and related matters:
CBP issued the following releases on commercial trade and related matters: